Active Biotech

Report Publication Announcement • May 18, 2017

PRESS RELEASE

Annual Report 2016 Active Biotech AB (publ)

Active Biotech's Annual Report 2016 is now available för download at www.activebiotech.com.

The Annual Report will only be digitally distributed. The English version will be available within short.

Lund, May 18, 2017

Tomas Leanderson President & CEO

For further information, please contact: Hans Kolam, CFO Tel. +46 (0)46 192044

About Active Biotech

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in Phase 2 development for the treatment of primary progressive multiple sclerosis and Huntington's disease. Anyara, cancer immunotherapy, previously in clinical Phase 1-2/3 development in patients with pancreatic-, lung- or renal cancer. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit www.activebiotech.com for more information.

Active Biotech AB PO Box 724, SE-220 07 Lund Sweden Tel: +46 (0)46-19 20 00

This information is information that Active Biotech AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 14.30 am CET on May 18, 2017.